GORE® CARDIOFORM Septal Occluder Migraine Clinical Study (RELIEF)

GORE® CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to Evaluate the Safety and Efficacy of Transcatheter Closure of Patent Foramen Ovale for Relief of Migraine Headaches

Multi-center, prospective, randomized, placebo- and sham-controlled study to evaluate the GORE® CARDIOFORM Septal Occluder for migraine headache relief

Study Overview

• Status: Recruiting
• Conditions: Migraine; Patent Foramen Ovale; PFO - Patent Foramen Ovale
• Intervention / Treatment: Device: Actual device PFO closure; Drug: Thienopyridine (clopidogrel or prasugrel); Device: Sham device PFO closure

• Study Type: Interventional
• Enrollment (Estimated): 150
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Erik Ramirez; Phone Number: 480-828-5597; Email: relief@wlgore.com

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85054
      • Recruiting
      • Mayo Clinic Arizona
      • Contact: Daivd Fortuin, MD
  • California
    • Los Angeles, California, United States, 90095
      • Recruiting
      • UCLA Health
      • Contact: John Tobis, MD
    • Santa Barbara, California, United States, 93105
      • Recruiting
      • Santa Barbara Cottage Hospital Research Institute
      • Contact: Joseph Aragon, MD
  • Colorado
    • Denver, Colorado, United States, 80120
      • Recruiting
      • South Denver Cardiology
      • Contact: Lee MacDonald, MD
    • Loveland, Colorado, United States, 80538
      • Recruiting
      • Medical Center of the Rockies
      • Contact: Justin Strote, MD
  • Connecticut
    • New Haven, Connecticut, United States, 06510
      • Recruiting
      • Yale University School Of Medicine
      • Contact: Jeremy Asnes, MD
  • Iowa
    • West Des Moines, Iowa, United States, 50314
      • Recruiting
      • Mercy One Iowa Heart Center
      • Contact: Mark Tannenbaum, MD
  • Kentucky
    • Lexington, Kentucky, United States, 40536
      • Withdrawn
      • University of Kentucky Research Foundation
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Recruiting
      • Massachusetts General Hospital
      • Contact: Ignacio Inglessis, MD
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Recruiting
      • University of Michigan Hospital
      • Contact: Michael Grossman, MD
  • New York
    • Buffalo, New York, United States, 14203
      • Recruiting
      • University at Buffalo
      • Contact: David Zlotnick, MD
    • Liverpool, New York, United States, 13088
      • Recruiting
      • SJH Cardiology Associates
      • Contact: Ayman Iskander, MD
    • New York, New York, United States, 10032
      • Recruiting
      • Columbia University Medical Center
      • Contact: Robert Sommer, MD; Email: reliefstudy@columbia.edu
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Recruiting
      • Medical University of South Carolina
      • Contact: John Rhodes, MD
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Recruiting
      • Medical College of Wisconsin
      • Contact: Michael Cinquegrani, MD
    • Milwaukee, Wisconsin, United States, 53215
      • Recruiting
      • Aurora St Luke's Medical Center
      • Contact: Tanvir Bajwa, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Subject is 18-55 years of age at the screening visit.
2. Subject is willing and capable of complying with the study protocol requirements, including the specified follow-up period, and can be contacted by telephone.
3. Subject signed an Informed Consent Form prior to study participation.
4. Subject's symptoms meet International Classification of Headache Disorders - 3 (ICHD-3) Diagnostic Criteria for migraine with or without aura.
5. Subject has at least one year of migraine symptom duration.
6. Subject had migraine onset younger than 50 years of age.
7. Subject has more than one migraine headache day per week on average by history - headache day defined as: headache that meets ICHD-3 criteria for migraine or probable migraine with or without aura and lasts at least four hours or administration of acute medication before four hours (regardless of clinical response to acute medication).
8. Subject has tried and failed at least two preventive medications at adequate dosage for an adequate duration, in the judgement of the study site neurologist, and be from two separate classifications of the following classes of drugs: antidepressants, antihypertensive, anticonvulsant, onabotulinumtoxin A, CGRP inhibitors or other treatments with at least one positive randomized placebo-controlled trial (See APPENDIX A).
9. Subject must exhibit stable dosage on their preventive migraine medication for at least two months prior to the screening visit and agree to continue preventive medication at current dosage throughout the duration of the study.
10. Female subjects are currently not pregnant, breastfeeding or lactating and not planning pregnancy during their participation in the study.
11. Female subjects capable of becoming pregnant agree to use birth control or abstinence during their participation in the study.
12. Presence of Patent Foramen Ovale (PFO), as determined initially by positive bubble study utilizing Transthoracic Echocardiography (TTE) or transesophageal echocardiography (TEE), demonstrating right-to-left shunting.
13. Subject is willing to complete daily electronic migraine headache log.
14. Subject is not planning surgery during their participation the study.

Exclusion Criteria:

1. Subject is currently enrolled in any pre-approval investigational study. (Does not apply to long-term post-market studies unless participation might interfere clinically with the RELIEF endpoints.)
2. Subject has known organic issues which may cause headaches (e.g., temporo-mandibular joint, brain tumor, cervical spinal issues, known seizure disorder, etc.).
3. Subjects with hemicrania continua, post-traumatic headache, or other trigeminal autonomic cephalalgia secondary headache disorders.
4. Subject has known hypersensitivity or contraindication to thienopyridines.
5. Subject is currently taking a P2Y12 inhibitor (See APPENDIX B).
6. Subject has need for chronic oral anticoagulation therapy (e.g., atrial fibrillation, mechanical heart valve, etc.) (See APPENDIX B).
7. Subject has need for chronic antiplatelet therapy.
8. Subject has need for daily use of non-steroidal anti-inflammatory drugs (NSAIDs) (See APPENDIX B).
9. Subject has a history of thrombocytopenia within one year, or platelet count <100,000 mm3 identified during the screening phase.
10. Subject has severe hepatic impairment with reduced synthetic function as documented by prolongation of PT/PTT or total bilirubin > 3.0 mg/dL identified during the screening phase.
11. Subject has any history of stroke, TIA, or intracranial hemorrhage.
12. Subject has previously implanted pacemaker, IVC filter, PFO closure device, ASD closure device, left atrial appendage closure device OR any cardiac surgical or interventional history which, in the investigator's opinion, would preclude them from study participation.
13. Subject has documented right-to-left shunt source in addition to PFO, such as pulmonary arteriovenous malformation.
14. Subject used opioids, marijuana (medical or recreational) or butalbital-containing medications for acute migraine headache treatment four or more times per month on average within the past six months.
15. Subject abuses alcohol and/or drugs in the opinion of the Investigator.
16. Subject is unable to understand the study requirements or has a history of non-compliance with medical advice.
17. Subject has a history of clinically significant bleeding within six months of the screening visit, any active bleeding, or active peptic ulcer disease.
18. Subject has an uncontrolled arrhythmia or, if on therapy, within the past 90 days has evidence of arrhythmia control failure (e.g., supraventricular tachycardia while under rate control or atrial fibrillation while under rhythm control).
19. Subject has elevated pulmonary vascular resistance (PVR) which, in the opinion of the implanting physician, precludes safe defect closure.
20. Subject has uncontrolled systemic hypertension at the time of screening, in the opinion of the investigator.
21. In the opinion of the Investigator, patient has anatomic criteria identified during the screening evaluation and/or the screening echocardiogram that are unfavorable for successful placement of the GORE® CARDIOFORM Septal Occluder.
22. Subject has active infection at the time of screening that cannot be treated.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test Arm; Device PFO closure with the GORE® CARDIOFORM Septal Occluder	Device: Actual device PFO closure; Actual PFO closure with the GORE® CARDIOFORM Septal Occluder; Other Names: GORE® CARDIOFORM Septal Occluder; Drug: Thienopyridine (clopidogrel or prasugrel); Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure; Other Names: Plavix; Effient
Sham Comparator: Control Arm; Sham device PFO closure (PFO not closed)	Drug: Thienopyridine (clopidogrel or prasugrel); Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure; Other Names: Plavix; Effient; Device: Sham device PFO closure; Sham (simulated) device PFO closure with result of no device implantation and no PFO closure

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction in Migraine Headache Days: mean reduction in the number of migraine headache days per month from baseline to follow-up headache days per month from baseline to follow-up	Primary Efficacy Endpoint	Week 40
Proportion of subjects with any Serious Adverse Event (SAE) related to the study device or study procedure through 30 days post-procedure	Primary Safety Endpoint	30 days post-procedure

Collaborators and Investigators

• Sponsor: W.L.Gore & Associates
• Investigators: Principal Investigator: Robert Sommer, MD, Columbia University; Principal Investigator: David Dodick, MD, Mayo Clinic

Study record dates

Study Major Dates

• Study Start (Actual): February 5, 2021
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): August 1, 2027

Study Registration Dates

• First Submitted: September 20, 2019
• First Submitted That Met QC Criteria: September 23, 2019
• First Posted (Actual): September 24, 2019

Study Record Updates

• Last Update Posted (Actual): February 26, 2024
• Last Update Submitted That Met QC Criteria: February 22, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Migraine; Patent Foramen Ovale; PFO; Migraine aura
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Congenital Abnormalities; Headache Disorders, Primary; Headache Disorders; Heart Defects, Congenital; Cardiovascular Abnormalities; Heart Septal Defects, Atrial; Heart Septal Defects; Migraine Disorders; Foramen Ovale, Patent; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Purinergic P2 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents; Clopidogrel; Prasugrel Hydrochloride
• Other Study ID Numbers: GSO 17-03

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes